Bedrijfsoverzicht
Enanta Pharmaceuticals, Inc. is a biotechnology enterprise dedicated to the discovery and development of small molecule drugs designed for virology and immunology indications. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high degree of scientific risk and significant investment in research and development activities. With a market capitalization of $409.46M, the firm employs approximately 120 individuals and generated total revenue of $66.98M over the trailing twelve-month period. These financial figures indicate that the company is a mid-sized entity within the biotech landscape, possessing a substantial cash reserve relative to its annual sales but operating without profitability at the current stage of its development cycle.
Financiële gezondheid
The company reported a revenue of $66.98M, a net income of $-71,537,000, and an EBITDA of $-68,132,000 during the trailing twelve months. The significant negative gap between the positive revenue of $66.98M and the substantial net loss reveals a cost structure dominated by research expenses, administrative overhead, and potentially clinical trial costs that far exceed current sales generation. Free cash flow stood at $-1,043,125, indicating that the company is currently burning cash, which limits its financial flexibility and necessitates ongoing capital raising or reliance on existing reserves to fund operations. Gross margin is reported at 100.0%, suggesting that cost of goods sold is negligible or zero for the current product portfolio, while the operating margin of -60.5% and profit margin of -106.8% highlight the intense expense burden inherent in the pre-revenue or early-revenue biotechnology phase. The firm holds $185.85M in cash against $193.18M in debt, resulting in a debt-to-equity ratio of 152.60, which characterizes a highly leveraged balance sheet where debt obligations exceed liquid assets. Despite the leverage, the current ratio is 4.44, indicating a robust short-term liquidity position where current assets significantly outweigh current liabilities. Furthermore, the return on equity is -60.0% and the return on assets is -13.5%, metrics that reveal that management is currently destroying shareholder value and utilizing assets to generate losses rather than returns.
Waarderingsbeoordeling
Enanta Pharmaceuticals presents a challenging valuation landscape with a P/E ratio (TTM) of N/A and a forward P/E of -6.39, implying that earnings are negative and traditional trailing multiples are inapplicable, while the negative forward P/E suggests market expectations of continued losses or a transition to profitability are priced into the stock. The price-to-book ratio stands at 3.23, indicating that the market values the company at more than three times its net asset value, which often reflects the high value placed on the company's intellectual property and potential clinical assets despite current financial deficits. Alternative valuation metrics such as the price-to-sales ratio of 6.11 and an EV/EBITDA of -6.12 suggest that investors are pricing the stock based on revenue potential and future clinical milestones rather than current earnings power. The stock has experienced significant volatility, trading between a 52-week low of $4.55 and a 52-week high of $17.15. Without a specific current price provided in the source facts, the valuation range indicates a wide band of investor sentiment, with the stock capable of trading at levels reflecting either deep value or significant risk premium relative to its historical 52-week performance. The beta value of 1.00 indicates that the stock's price volatility mirrors the broader market movements, suggesting it does not exhibit higher or lower systemic risk than the general equity market index.
Growth & Income
Revenue growth year-over-year is recorded at 9.8%, while earnings growth is N/A due to the company's lack of profitability. The disparity between positive revenue growth and non-existent earnings growth implies that top-line expansion is occurring but is not yet translating into bottom-line profit, a common characteristic of early-stage biotechnology firms investing heavily in pipelines like EDP-514. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically reinvested into growth initiatives, although current net income is negative, necessitating the use of cash reserves for operational expansion. The overall growth and income profile is defined by revenue expansion without income distribution, relying entirely on the successful advancement of its clinical pipeline to eventually generate positive cash flows and shareholder returns.